With a legacy of innovation since the 1800s, a global biopharma company rallies around its mission to bring life-saving medicines to people with serious diseases. Over the last several years, that has meant consolidating its broad product portfolio to more focused solutions while expanding into promising new therapeutic areas, including cell and gene therapy.

As the organization began reinventing itself as a cutting-edge biopharma company, leadership realized that it also needed to rethink its real estate footprint.

The company continues to make progress in rolling out its real estate strategy, designed to support its mission to drive scientific breakthroughs. Since 2020, JLL has been instrumental in the transition of more than 20 of the company’s global real estate assets, including the sale of several large and complex campuses. The team also helped revitalize a number of legacy campuses, allowing the company to bolster the communities where it does business.

With a large team providing support across the extensive biopharma real estate portfolio and facilities for several years, JLL has connected pillars across the organization, offered historical knowledge and helped maintain a culture of excellence in facilities management. Additionally, JLL’s expertise in sustainability, workplace strategy, and diversity, equity and inclusion has inspired the company’s real estate team as it looks to the future.

The right real estate locations for attracting talent and managing global supply chains will continue to shift as science evolves and new therapies emerge. As the biopharma company reshapes its global real estate footprint, JLL remains a preferred partner to support location strategy and site selection, divestitures, and ongoing management of its existing portfolio and facilities. By supporting where the company is heading, JLL is helping it to fulfill its mission to deliver life-saving medicines to patients.

Ready to take a fresh look at your own portfolio strategy? Contact us today.